Bile salt inhibition of host cell damage by Clostridium difficile toxins

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Darkoh, Charles ^a,b   Brown, Eric L ^a   Kaplan, Heidi B ^b,c   DuPont, Herbert L ^a,b,c,d,e  

^a UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d ST LUKE S EPISCOPAL HOSPITAL   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; LACTATE DEHYDROGENASE; TAUROCHOLIC ACID; BACTERIAL PROTEIN; BACTERIAL TOXIN; BILE ACID; TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DAMAGE; CELL PROTECTION; CLOSTRIDIUM DIFFICILE; COLON MUCOSA; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; EX VIVO STUDY; HUMAN; HUMAN CELL; INTESTINE CELL; MEMBRANE DAMAGE; NONHUMAN; CACO 2 CELL LINE; CELL MEMBRANE; DRUG EFFECTS; ISOLATION AND PURIFICATION; METABOLISM; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMEMBRANOUS COLITIS; TOXICITY;

BACTERIAL PROTEINS; BACTERIAL TOXINS; BILE ACIDS AND SALTS; CACO-2 CELLS; CASPASE 3; CELL MEMBRANE; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; HUMANS; TAUROCHOLIC ACID;

EID: 84893190401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079631     Document Type: Article

References (71)

1. DuPont HL (2011) The search for effective treatment of Clostridium difficile infection. N England J Med 364: 473-475.
2. Lyerly DM, Saum KE, MacDonald DK, Wilkins TD (1985) Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47: 349-352. (Pubitemid 15169828)
3. Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs SL (2001) Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiol 147: 439-447. (Pubitemid 32156820)
4. Geric B, Rupnik M, Gerding DN, Grabnar M, Johnson S (2004) Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 53: 887-894. (Pubitemid 39238395)
5. Voth DE, Ballard JD (2005) Clostridium difficile toxins: mechanism of action and role in disease. Clin Microbiol Rev 18: 247-263. (Pubitemid 40548293)
6. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, et al. (2010) The role of toxin A and toxin B in Clostridium difficile infection. Nature 467: 711-713.
7. Dillon ST, Rubin EJ, Yakubovich M, Pothoulakis C, LaMont JT, et al. (1995) Involvement of Ras-related Rho proteins in the mechanisms of action of Clostridium difficile toxin A and toxin B. Infect Immun 63: 1421-1426.
8. Just I, Selzer J, Wilm M, von Eichel-Streiber C, Mann M, et al. (1995) Glucosylation of Rho proteins by Clostridium difficile toxin B. Nature 375: 500-503.
9. Just I, Wilm M, Selzer J, Rex G, von Eichel-Streiber C, et al. (1995) The enterotoxin from Clostridium difficile (ToxA) monoglucosylates the Rho proteins. J Biol Chem 270: 13932-13936.
10. Von Eichel-Streiber C, Boquet P, Sauerborn M, Thelestam M (1996) Large clostridial cytotoxins - a family of glycosyltransferases modifying small GTP-binding proteins. Trends Microbiol 4: 375-382. (Pubitemid 26325127)
11. Just I, Gerhard R (2004) Large clostridial cytotoxins. Rev Physiol Biochem Pharmacol 152: 23-47. (Pubitemid 44404356)
12. Ho JG, Greco A, Rupnik M, Ng KK (2005) Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. Proc Natl Acad Sci U S A 102: 18373-18378. (Pubitemid 43011233)
13. Dingle T, Wee S, Mulvey GL, Greco A, Kitova EN, et al. (2008) Functional properties of the carboxy-terminal host cell-binding domains of the two toxins, TcdA and TcdB, expressed by Clostridium difficile . Glycobiol 18: 698-706.
14. Hofmann F, Busch C, Prepens U, Just I, Aktories K (1997) Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J Biol Chem 272: 11074-11078. (Pubitemid 27184097)
15. Egerer M, Giesemann T, Jank T, Satchell KJ, Aktories K (2007) Auto-catalytic cleavage of Clostridium difficile toxins A and B depends on cysteine protease activity. J Biol Chem 282: 25314-25321. (Pubitemid 47372781)
16. Reineke J, Tenzer S, Rupnik M, Koschinski A, Hasselmayer O, et al. (2007) Autocatalytic cleavage of Clostridium difficile toxin B. Nature 446: 415-419. (Pubitemid 46474600)
17. Pfeifer G, Schirmer J, Leemhuis J, Busch C, Meyer DK, et al. (2003) Cellular uptake of Clostridium difficile toxin B. Translocation of the N-terminal catalytic domain into the cytosol of eukaryotic cells. J Biol Chem 278: 44535-44541. (Pubitemid 37377206)
18. Rupnik M, Pabst S, von Eichel-Streiber C, Urlaub H, Soling HD (2005) Characterization of the cleavage site and function of resulting cleavage fragments after limited proteolysis of Clostridium difficile toxin B (TcdB) by host cells. Microbiol 151: 199-208. (Pubitemid 40214335)
19. Genth H, Dreger SC, Huelsenbeck J, Just I (2008) Clostridium difficile toxins: more than mere inhibitors of Rho proteins. Int J Biochem Cell Biol 40: 592-597.
20. Huelsenbeck SC, May M, Schmidt G, Genth H (2009) Inhibition of cytokinesis by Clostridium difficile toxin B and cytotoxic necrotizing factors - reinforcing the critical role of RhoA in cytokinesis. Cell Motil Cytoskeleton 66: 967-975.
21. Moser SA, Savage DC (2001) Bile salt hydrolase activity and resistance to toxicity of conjugated bile salts are unrelated properties in lactobacilli. Appl Environ Microbiol 67: 3476-3480. (Pubitemid 33641217)
22. Ridlon JM, Kang DJ, Hylemon PB (2006) Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47: 241-259. (Pubitemid 43276911)
23. Begley M, Hill C, Gahan CG (2006) Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 72: 1729-1738.
24. Hofmann AF (1999) The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 159: 2647-2658.
25. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, et al. (2006) Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci U S A 103: 3920-3925. (Pubitemid 43376656)
26. Sung JY, Shaffer EA, Costerton JW (1993) Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids. Dig Dis Sci 38: 2104-2112. (Pubitemid 23336578)
27. Lillienau J, Borgstrom B (1991) Bacterial deconjugation and enterohepatic circulation of norursocholic acid conjugates in rats. Am J Physiol 261: G1065-1071.
28. Tanaka H, Doesburg K, Iwasaki T, Mierau I (1999) Screening of lactic acid bacteria for bile salt hydrolase activity. J Dairy Sci 82: 2530-2535. (Pubitemid 129545899)
29. Jones BV, Begley M, Hill C, Gahan CG, Marchesi JR (2008) Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome. Proc Natl Acad Sci U S A 105: 13580-13585.
30. Huijghebaert SM, Mertens JA, Eyssen HJ (1982) Isolation of a bile salt sulfatase-producing Clostridium strain from rat intestinal microflora. Appl Environ Microbiol 43: 185-192. (Pubitemid 12137601)
31. Van Eldere J, Robben J, De Pauw G, Merckx R, Eyssen H (1988) Isolation and identification of intestinal steroid-desulfating bacteria from rats and humans. Appl Environ Microbiol 54: 2112-2117.
32. De Smet I, Van Hoorde L, Vande Woestyne M, Christiaens H, Verstraete W (1995) Significance of bile salt hydrolytic activities of Lactobacilli. J Appl Bacteriol 79: 292-301.
33. Pothoulakis C, Lamont JT (2001) Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 280: G178-183.
34. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, et al. (2012) Targeted restoration of the intestinal microbiota with a simple, defined bacteriotherapy resolves relapsing Clostridium difficile disease in mice. PLoS Pathogens 8: e1002995.
35. Aronsson B, Mollby R, Nord CE (1985) Antimicrobial agents and Clostridium difficile in acute enteric disease: epidemiological data from Sweden, 1980-1982. The J Infect Dis 151: 476-481. (Pubitemid 15103799)
36. Bartlett JG (2009) New antimicrobial agents for patients with Clostridium difficile infections. Curr Infect Dis Rep 11: 21-28.
37. Bartlett JG (1992) Antibiotic-associated diarrhea. Clin Infect Dis 15: 573-581.
38. Bartlett JG (2002) Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 346: 334-339.
39. Bartlett JG, Gerding DN (2008) Clinical recognition and diagnosis of Clostridium difficile infection. Clin Infect Dis 46 Suppl 1: S12-18. (Pubitemid 351323661)
40. Bishara J, Bloch Y, Garty M, Behor J, Samra Z (2006) Antimicrobial resistance of Clostridium difficile isolates in a tertiary medical center, Israel. Diagn Microbiol Infect Dis 54: 141-144. (Pubitemid 43176604)
41. Aspevall O, Lundberg A, Burman LG, Akerlund T, Svenungsson B (2006) Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother 50: 1890-1892.
42. Shubeita HE, Sambrook JF, McCormick AM (1987) Molecular cloning and analysis of functional cDNA and genomic clones encoding bovine cellular retinoic acid-binding protein. Proc Natl Acad Sci U S A 84: 5645-5649.
43. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, et al. (2002) Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 46: 1647-1650. (Pubitemid 34535177)
44. Aas J, Gessert CE, Bakken JS (2003) Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 36: 580-585. (Pubitemid 36259562)
45. Brandt LJ (2012) Fecal transplantation for the treatment of Clostridium difficile infection. Gastroenterol Hepatol (N Y) 8: 191-194.
46. Mattila E, Uusitalo-Seppala R, Wuorela M, Lehtola L, Nurmi H, et al. (2012) Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterol 142: 490-496.
47. Kelly CR, de Leon L, Jasutkar N (2012) Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol 46: 145-149.
48. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, et al. (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362: 197-205.
49. McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, et al. (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 271: 1913-1918. (Pubitemid 24177098)
50. Borriello SP, Barclay FE (1985) Protection of hamsters against Clostridium difficile ileocaecitis by prior colonisation with non-pathogenic strains. J Med Microbiol 19: 339-350. (Pubitemid 15027247)
51. Wilson KH, Sheagren JN (1983) Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis 147: 733-736. (Pubitemid 13088248)
52. Sambol SP, Merrigan MM, Tang JK, Johnson S, Gerding DN (2002) Colonization for the prevention of Clostridium difficile disease in hamsters. J Infect Dis 186: 1781-1789. (Pubitemid 35463511)
53. Darkoh C, Kaplan HB, DuPont HL (2011) Harnessing the glucosyltransferase activities of Clostridium difficile for functional studies of toxins A and B. J Clin Microbiol 49: 2933-2941.
54. Darkoh C, DuPont HL, Kaplan HB (2011) Novel one-step method for detection and isolation of active-toxin-producing Clostridium difficile strains directly from stool samples. J Clin Microbiol 49: 4219-4224.
55. Brown EL, Xue Q, Jiang ZD, Xu Y, DuPont HL (2010) Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 54: 388-396.
56. Shikita M, Fahey JW, Golden TR, Holtzclaw WD, Talalay P (1999) An unusual case of 'uncompetitive activation' by ascorbic acid: purification and kinetic properties of a myrosinase from Raphanus sativus seedlings. Biochem J 341 (Pt 3): 725-732. (Pubitemid 29389204)
57. Northfield TC, McColl I (1973) Postprandial concentrations of free and conjugated bile acids down the length of the normal human small intestine. Gut 14: 513-518.
58. Gerhard R, Nottrott S, Schoentaube J, Tatge H, Olling A, et al. (2008) Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells. J Med Microbiol 57: 765-770. (Pubitemid 351842070)
59. Brito GA, Fujji J, Carneiro-Filho BA, Lima AA, Obrig T, et al. (2002) Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells. J Infect Dis 186: 1438-1447. (Pubitemid 35286111)
60. Carneiro BA, Fujii J, Brito GA, Alcantara C, Oria RB, et al. (2006) Caspase and bid involvement in Clostridium difficile toxin A-induced apoptosis and modulation of toxin A effects by glutamine and alanyl-glutamine in vivo and in vitro. Infect Immun 74: 81-87. (Pubitemid 43023061)
61. Porter AG, Janicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell death and differentiation 6: 99-104. (Pubitemid 29082297)
62. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P (2007) Caspases in cell survival, proliferation and differentiation. Cell death and differentiation 14: 44-55. (Pubitemid 44911893)
63. Yuan J, Horvitz HR (2004) A first insight into the molecular mechanisms of apoptosis. Cell 116: S53-56.
64. Brandes V, Schelle I, Brinkmann S, Schulz F, Schwarz J, et al. (2011) Protection from C. difficile Toxin B-catalysed Rac/Cdc42 glucosylation by tauroursodeoxycholic acid-induced Rac/Cdc42 phosphorylation. Biol Chem.
65. Dowling RH (1973) The enterohepatic circulation of bile acids as they relate to lipid disorders. J Clin Pathol Suppl (Assoc Clin Pathol) 5: 59-67.
66. Poupon RE, Balkau B, Eschwege E, Poupon R (1991) A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Eng J Med 324: 1548-1554.
67. Heuman DM, Pandak WM, Hylemon PB, Vlahcevic ZR (1991) Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatol 14: 920-926.
68. Heuman DM, Mills AS, McCall J, Hylemon PB, Pandak WM, et al. (1991) Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts. In vivo studies in the rat. Gastroenterol 100: 203-211.
69. Queneau PE, Bertault-Peres P, Mesdjian E, Durand A, Montet JC (1993) Diminution of an acute cyclosporin-induced cholestasis by tauroursodeoxycholate in the rat. Transplantation 56: 530-534. (Pubitemid 23293010)
70. Bailey ME (1976) Endotoxin, bile salts and renal function in obstructive jaundice. British J Surgery 63: 774-778.
71. Gouma DJ, Coelho JC, Fisher JD, Schlegel JF, Li YF, et al. (1986) Endotoxemia after relief of biliary obstruction by internal and external drainage in rats. Am J Surgery 151: 476-479. (Pubitemid 16037960)